Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | CBLB | Q13191 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2297613 | 0.93 | SMN1; SMN2 (0.51) | SMN1; SMN2RAB9ANPC1MAPTGAA | |
| SCHEMBL5302336 | 0.90 | SMN1; SMN2 (0.42) | SMN1; SMN2RAB9ANPC1MAPTGAA | |
| SCHEMBL2299761 | 0.89 | SMN1; SMN2 (0.49) | SMN1; SMN2RAB9ANPC1MAPTGAA | |
| SCHEMBL2297443 | 0.87 | CBLB (0.47) | SMN1; SMN2RAB9ANPC1MAPTCBLB | |
| SCHEMBL2299723 | 0.86 | GRM4 (0.48) | SMN1; SMN2RAB9ANPC1MAPTKDM4E | |
| SCHEMBL2298619 | 0.86 | RAB9A (0.52) | SMN1; SMN2RAB9ANPC1MAPTMEN1 | |
| SCHEMBL2294478 | 0.85 | NPC1 (0.48) | SMN1; SMN2RAB9ANPC1MAPTMEN1 | |
| SCHEMBL5302348 | 0.83 | MAPT (0.40) | SMN1; SMN2RAB9ANPC1MAPTGAA | |
| SCHEMBL5300582 | 0.83 | TP53 (0.45) | SMN1; SMN2RAB9ANPC1MAPTMEN1 | |
| SCHEMBL2298763 | 0.82 | NPC1 (0.37) | SMN1; SMN2RAB9ANPC1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003806-B2 | Integrin antagonists useful as anticancer agents | OSI Pharmaceuticals, LLC (US) | 2011-08-23 | — | — | US | claimed |
| EP-1828144-A2 | INTEGRIN ANTAGONISTS USEFUL AS ANTICANCER AGENTS | OSI Pharmaceuticals, Inc. (US) | 2007-09-05 | — | — | EP | claimed |
| US-20060116383-A1 | Integrin antagonists useful as anticancer agents | ALCATEL LUCENT (FR) | 2006-06-01 | — | — | US | claimed |
| WO-2006053342-A2 | INTEGRIN ANTAGONISTS USEFUL AS ANTICANCER AGENTS | OSI PHARMACEUTICALS, INC. (US) | 2006-05-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116383-A1 | Integrin antagonists useful as anticancer agents | ITGB5, ITGA5, ITGB1 | SMN1; SMN2 2159/4885RAB9A 1893/4885NPC1 2770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.